Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells
Related Experiment Video
Updated: Apr 27, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Wenwen Chien1, Ling-Wen Ding, Qiao-Yang Sun
1Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Abstract:
Endoplasmic reticulum stress from unfolded proteins is associated with the proliferation of pancreatic tumor cells, making the many regulatory molecules of this pathway appealing targets for therapy. The objective of our study was to assess potential therapeutic efficacy of inhibitors of unfolded protein response (UPR) in pancreatic cancers focusing on IRE1α inhibitors. IRE1α-mediated XBP-1 mRNA splicing encodes a transcription factor that enhances transcription of chaperone proteins in order to reverse UPR. Proliferation assays using a panel of 14 pancreatic cancer cell lines showed a dose- and time-dependent growth inhibition by IRE1α-specific inhibitors (STF-083010, 2-Hydroxy-1-naphthaldehyde, 3-Ethoxy-5,6-dibromosalicylaldehyde, toyocamycin). Growth inhibition was also noted using a clonogenic growth assay in soft agar, as well as a xenograft in vivo model of pancreatic cancer. Cell cycle analysis showed that these IRE1α inhibitors caused growth arrest at either the G1 or G2/M phases (SU8686, MiaPaCa2) and induced apoptosis (Panc0327, Panc0403). Western blot analysis showed cleavage of caspase 3 and PARP, and prominent induction of the apoptotic molecule BIM. In addition, synergistic effects were found between either STF-083010, 2-Hydroxy-1-naphthaldehyde, 3-Ethoxy-5,6-dibromosalicylaldehyde, or toyocamycin and either gemcitabine or bortezomib. Our data suggest that use of an IRE1α inhibitor is a novel therapeutic approach for treatment of pancreatic cancers.
Insights
IRE1α inhibitors show promise in treating pancreatic cancer by halting tumor cell growth and inducing apoptosis. These compounds also exhibit synergistic effects with existing chemotherapy drugs, offering a novel therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Endoplasmic reticulum stress and unfolded protein response (UPR) are linked to pancreatic tumor cell proliferation.
- IRE1α is a key regulator of the UPR pathway, making it a potential therapeutic target.
Purpose of the Study:
- To evaluate the therapeutic potential of IRE1α inhibitors in pancreatic cancer.
- To investigate the mechanisms of IRE1α inhibition on pancreatic cancer cell growth and survival.
Main Methods:
- Utilized proliferation assays across 14 pancreatic cancer cell lines with specific IRE1α inhibitors.
- Conducted clonogenic growth assays in soft agar and in vivo xenograft models.
- Performed cell cycle analysis and Western blot to assess apoptosis and molecular markers.
Main Results:
- IRE1α inhibitors demonstrated dose- and time-dependent growth inhibition in pancreatic cancer cells.
- Inhibitors induced cell cycle arrest (G1 or G2/M phases) and apoptosis, confirmed by caspase cleavage and BIM induction.
- Synergistic anti-cancer effects were observed when IRE1α inhibitors were combined with gemcitabine or bortezomib.
Conclusions:
- IRE1α inhibitors represent a novel and effective therapeutic approach for pancreatic cancer.
- Targeting the IRE1α pathway offers a promising strategy to overcome treatment resistance and improve patient outcomes.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
09:18Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
Related Concept Videos
Regulation of the Unfolded Protein Response
The Unfolded Protein Response
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Acute Pancreatitis II: Pathophysiology
Apoptosis